80 related articles for article (PubMed ID: 28960399)
1. Role of Intracystic Cytokines and Nitric Oxide in Ovarian Neoplasms.
Martins-Filho A; Jammal MP; Micheli DC; Tavares-Murta BM; Etchebehere RM; Murta EFC; Nomelini RS
Scand J Immunol; 2017 Dec; 86(6):462-470. PubMed ID: 28960399
[TBL] [Abstract][Full Text] [Related]
2. IL-6 and IL-8 as Prognostic Factors in Peritoneal Fluid of Ovarian Cancer.
Rodrigues ISS; Martins-Filho A; Micheli DC; Lima CA; Tavares-Murta BM; Murta EFC; Nomelini RS
Immunol Invest; 2020 Jul; 49(5):510-521. PubMed ID: 31755326
[TBL] [Abstract][Full Text] [Related]
3. Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours.
Daraï E; Detchev R; Hugol D; Quang NT
Hum Reprod; 2003 Aug; 18(8):1681-5. PubMed ID: 12871882
[TBL] [Abstract][Full Text] [Related]
4. Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer.
Sanguinete MMM; Oliveira PH; Martins-Filho A; Micheli DC; Tavares-Murta BM; Murta EFC; Nomelini RS
Immunol Invest; 2017 Oct; 46(7):677-688. PubMed ID: 28872976
[TBL] [Abstract][Full Text] [Related]
5. [Serum cytokines in patients with ovarian cancer and benign ovarian cysts].
Nowak M; Szpakowski M; Malinowski A; Wieczorek A; Maciołek-Blewniewska G; Wilczyński JR; Szpakowski A; Wierzbicka E; Małafiej E; Oszukowski P
Ginekol Pol; 2001 Dec; 72(12A):1444-8. PubMed ID: 11883294
[TBL] [Abstract][Full Text] [Related]
6. Cytokines in peritoneal fluid of ovarian neoplasms.
de Lima CA; Silva Rodrigues IS; Martins-Filho A; Côbo Micheli D; Martins Tavares-Murta B; Candido Murta EF; Simões Nomelini R
J Obstet Gynaecol; 2020 Apr; 40(3):401-405. PubMed ID: 31476946
[TBL] [Abstract][Full Text] [Related]
7. IL6, IL8, and IL10 in the distinction of malignant ovarian neoplasms and endometriomas.
Crispim PCA; Jammal MP; Antão PKA; Micheli DC; Tavares-Murta BM; Murta EFC; Nomelini RS
Am J Reprod Immunol; 2020 Dec; 84(6):e13309. PubMed ID: 32698242
[TBL] [Abstract][Full Text] [Related]
8. Clinical importance of determination of cytokines in patients with ovary tumours.
Abdullaeva LM
Lik Sprava; 2010; (3-4):56-9. PubMed ID: 21261134
[TBL] [Abstract][Full Text] [Related]
9. Intracystic evaluation of tumor markers in benign and malignant ovarian pathology.
Cherchi PL; Capobianco G; Ambrosini G; Fadda GM; Piga MD; Ruiu G; Fattorini F; Dessole S
Eur J Gynaecol Oncol; 2002; 23(2):163-5. PubMed ID: 12013118
[TBL] [Abstract][Full Text] [Related]
10. Differential tumor microenvironment in human ovarian cystic tumors.
Tavares Murta BM; Cunha Fde Q; Miranda R; Adad SJ; Murta EF
Tumori; 2004; 90(5):491-7. PubMed ID: 15656335
[TBL] [Abstract][Full Text] [Related]
11. The chemotactic cytokine interleukin-8--a cyst fluid marker for malignant epithelial ovarian cancer?
Ivarsson K; Runesson E; Sundfeldt K; Haeger M; Hedin L; Janson PO; Brännström M
Gynecol Oncol; 1998 Dec; 71(3):420-3. PubMed ID: 9887242
[TBL] [Abstract][Full Text] [Related]
12. Serum and peritoneal fluid concentrations of soluble human leukocyte antigen, tumor necrosis factor alpha and interleukin 10 in patients with selected ovarian pathologies.
Sipak-Szmigiel O; Włodarski P; Ronin-Walknowska E; Niedzielski A; Karakiewicz B; Słuczanowska-Głąbowska S; Laszczyńska M; Malinowski W
J Ovarian Res; 2017 Apr; 10(1):25. PubMed ID: 28376925
[TBL] [Abstract][Full Text] [Related]
13. [Significantly increased interleukin-1A and interleukin-1 soluble type II receptor levels in women with ovarian cancer].
Kondera-Anasz Z; Mielczarek-Palacz A; Switała J
Ginekol Pol; 2003 Sep; 74(9):761-6. PubMed ID: 14674121
[TBL] [Abstract][Full Text] [Related]
14. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer.
Zeimet AG; Widschwendter M; Knabbe C; Fuchs D; Herold M; Müller-Holzner E; Daxenbichler G; Offner FA; Dapunt O; Marth C
J Clin Oncol; 1998 May; 16(5):1861-8. PubMed ID: 9586902
[TBL] [Abstract][Full Text] [Related]
15. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
[TBL] [Abstract][Full Text] [Related]
16. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors.
Candido Dos Reis F; Moreira de Andrade J; Bighetti S
Gynecol Obstet Invest; 2002; 54(3):132-6. PubMed ID: 12571433
[TBL] [Abstract][Full Text] [Related]
17. Serum cytokines and CXCR2: potential tumour markers in ovarian neoplasms.
Micheli DC; Jammal MP; Martins-Filho A; Côrtes JRXM; Souza CN; Nomelini RS; Murta EFC; Tavares-Murta BM
Biomarkers; 2020 Sep; 25(6):474-482. PubMed ID: 32544350
[TBL] [Abstract][Full Text] [Related]
18. Production of interleukin-1 beta and tumour necrosis factor-alpha in patients with benign or malignant ovarian tumours.
Punnonen J; Heinonen PK; Kuoppala T; Jansen CT; Punnonen R
J Cancer Res Clin Oncol; 1991; 117(6):587-92. PubMed ID: 1744165
[TBL] [Abstract][Full Text] [Related]
19. Production of nitric oxide and expression of inducible nitric oxide synthase in ovarian cystic tumors.
Nomelini RS; de Abreu Ribeiro LC; Tavares-Murta BM; Adad SJ; Murta EF
Mediators Inflamm; 2008; 2008():186584. PubMed ID: 19132106
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal cytokine level in patients with peritoneal surface malignancies. A study of the RENAPE (French Network for Rare Peritoneal Malignancies).
Vlaeminck-Guillem V; Bienvenu J; Isaac S; Grangier B; Golfier F; Passot G; Bakrin N; Rodriguez-Lafrasse C; Gilly FN; Glehen O
Ann Surg Oncol; 2013 Aug; 20(8):2655-62. PubMed ID: 23519518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
